Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Inclusion Criteria: * Histologically or cytologically confirmed low or intermediate grade neuroendocrine carcinoma including carcinoid and islet cell cancer. Patients with neuroendocrine tumors associated with MEN1 syndrome are eligible. * Measureable disease by RECIST * Unresectable or metastatic disease * Secretory symptoms of diarrhea or flushing or both attributed to their carcinoid tumor and/or quantifiable hormones or other biochemical markers * Males and females 18 years of age or older. * Zero to two prior cytotoxic chemotherapy regimens. * Patients may be receiving concomitant octreotide Sandostatin® * Patients must have central IV access, or agree to the insertion of a central IV line. * All previous cancer therapies, radiation, and surgery, must have been discontinued at least 21 days prior to the start of treatment. * Acceptable liver function * Acceptable renal function * Acceptable hematologic status * ECOG Performance Status ≤1. * Anticipated survival of at least 6 months. * Able to maintain a patient diary. * For men and women of child-producing potential, use of effective contraceptive methods during the study and for one month after discontinuation of treatment. * Ability to understand the requirements of the study, provide written informed consent and agree to abide by the study restrictions and return to the clinic for required assessments. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid or small cell carcinoma. * Pregnant or nursing women. * Severe chronic obstructive pulmonary disease with hypoxemia or an uncorrectable pulmonary compromise. * Seizures not controlled by anticonvulsant therapy. * Participation in any investigational drug study within 28 days before quarfloxin administration or currently receiving investigational therapy. * Patients with a second malignancy requiring active treatment. * Active symptomatic bacterial, fungal, or viral infection including active HIV or viral hepatitis. * Prior treatment with quarfloxin. * Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis. * Patients who have exhibited allergic reactions to a similar structural compound or formulation. * Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any of the study's endpoints.